{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:26:55Z","timestamp":1772515615161,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T00:00:00Z","timestamp":1503360000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s13365-017-0560-x","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T10:45:11Z","timestamp":1503398711000},"page":"734-741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2239-7681","authenticated-orcid":false,"given":"Pabitra","family":"Basnyat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elina","family":"Virtanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Elovaara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanna","family":"Hagman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eeva","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"key":"560_CR1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40291-016-0236-x","volume":"21","author":"E Auvinen","year":"2017","unstructured":"Auvinen E (2017) Diagnostic and prognostic value of MicroRNA in viral diseases. Mol Diagn Ther 21:45\u201357","journal-title":"Mol Diagn Ther"},{"key":"560_CR2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.msard.2015.06.008","volume":"4","author":"P Basnyat","year":"2015","unstructured":"Basnyat P, Hagman S, Kolasa M, Koivisto K, Verkkoniemi-Ahola A, Airas L, Elovaara I (2015) Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients. Mult Scler Relat Disord 4:334\u2013338","journal-title":"Mult Scler Relat Disord"},{"key":"560_CR3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chom.2011.01.008","volume":"9","author":"Y Bauman","year":"2011","unstructured":"Bauman Y, Nachmani D, Vitenshtein A, Tsukerman P, Drayman N, Stern-Ginossar N, Lankry D, Gruda R, Mandelboim O (2011) An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host Microbe 9:93\u2013102","journal-title":"Cell Host Microbe"},{"key":"560_CR4","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870\u20131880","journal-title":"N Engl J Med"},{"key":"560_CR5","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1073\/pnas.1301907110","volume":"110","author":"NM Broekema","year":"2013","unstructured":"Broekema NM, Imperiale MJ (2013) miRNA regulation of BK polyomavirus replication during early infection. Proc Natl Acad Sci U S A 110:8200\u20138205","journal-title":"Proc Natl Acad Sci U S A"},{"key":"560_CR6","doi-asserted-by":"crossref","first-page":"12683","DOI":"10.1128\/JVI.01933-14","volume":"88","author":"CJ Chen","year":"2014","unstructured":"Chen CJ, Burke JM, Kincaid RP, Azarm KD, Mireles N, Butel JS, Sullivan CS (2014) Naturally arising strains of polyomaviruses with severely attenuated microRNA expression. J Virol 88:12683\u201312693","journal-title":"J Virol"},{"key":"560_CR7","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","volume":"361","author":"Y Chen","year":"2009","unstructured":"Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361:1067\u20131074","journal-title":"N Engl J Med"},{"key":"560_CR8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438\u2013446","journal-title":"Lancet Neurol"},{"key":"560_CR9","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/1352458514531843","volume":"20","author":"GR Cutter","year":"2014","unstructured":"Cutter GR, Stuve O (2014) Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Mult Scler 20:1304\u20131305","journal-title":"Mult Scler"},{"key":"560_CR10","first-page":"73","volume":"13","author":"S Delbue","year":"2007","unstructured":"Delbue S, Guerini FR, Mancuso R, Caputo D, Mazziotti R, Saresella M, Ferrante P (2007) JC virus viremia in interferon-beta -treated and untreated Italian multiple sclerosis patients and healthy controls. J Neuro-Oncol 13:73\u201377","journal-title":"J Neuro-Oncol"},{"key":"560_CR11","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14740338.2015.1093620","volume":"14","author":"M Faulkner","year":"2015","unstructured":"Faulkner M (2015) Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Expert Opin Drug Saf 14:1737\u20131748","journal-title":"Expert Opin Drug Saf"},{"key":"560_CR12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","volume":"25","author":"MW Ferenczy","year":"2012","unstructured":"Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO (2012) Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25:471\u2013506","journal-title":"Clin Microbiol Rev"},{"key":"560_CR13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1212\/WNL.0000000000002330","volume":"86","author":"MS Gagne Brosseau","year":"2016","unstructured":"Gagne Brosseau MS, Stobbe G, Wundes A (2016) Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay. Neurology 86:484\u2013486","journal-title":"Neurology"},{"key":"560_CR14","first-page":"666","volume":"21","author":"I Giovannelli","year":"2015","unstructured":"Giovannelli I, Martelli F, Repice A, Massacesi L, Azzi A, Giannecchini S (2015) Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy. J Neuro-Oncol 21:666\u2013670","journal-title":"J Neuro-Oncol"},{"key":"560_CR15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/1352458513513208","volume":"20","author":"S Jilek","year":"2013","unstructured":"Jilek S, Mathias A, Canales M, Lysandropoulos A, Pantaleo G, Schluep M, Du Pasquier RA (2013) Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 alpha-chain (CD11a) in MS patients. Mult Scler 20:837\u2013842","journal-title":"Mult Scler"},{"key":"560_CR16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(10)70006-5","volume":"9","author":"S Jilek","year":"2010","unstructured":"Jilek S, Jaquiery E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, Schluep M, Pantaleo G, Du Pasquier RA (2010) Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 9:264\u2013272","journal-title":"Lancet Neurol"},{"key":"560_CR17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1212\/01.wnl.0000257832.38943.2b","volume":"68","author":"K Khalili","year":"2007","unstructured":"Khalili K, White MK, Lublin F, Ferrante P, Berger JR (2007) Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 68:985\u2013990","journal-title":"Neurology"},{"key":"560_CR18","first-page":"1884","volume":"72","author":"J Kira","year":"2014","unstructured":"Kira J (2014) Disease concept, etiology and mechanisms of multiple sclerosis. Nihon Rinsho 72:1884\u20131894","journal-title":"Nihon Rinsho"},{"key":"560_CR19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/ane.12475","volume":"133","author":"M Kolasa","year":"2016","unstructured":"Kolasa M, Hagman S, Verkkoniemi-Ahola A, Airas L, Koivisto K, Elovaara I (2016) Anti-JC virus seroprevalence in a Finnish MS cohort. Acta Neurol Scand 133:391\u2013397","journal-title":"Acta Neurol Scand"},{"key":"560_CR20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ymeth.2010.01.032","volume":"50","author":"EM Kroh","year":"2010","unstructured":"Kroh EM, Parkin RK, Mitchell PS, Tewari M (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50:298\u2013301","journal-title":"Methods"},{"key":"560_CR21","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452","journal-title":"Neurology"},{"key":"560_CR22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1743-422X-11-158","volume":"11","author":"O Lagatie","year":"2014","unstructured":"Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ (2014) Viral miRNAs in plasma and urine divulge JC polyomavirus infection. Virol J 11:158\u2013166","journal-title":"Virol J"},{"key":"560_CR23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/1743-422X-10-268","volume":"10","author":"O Lagatie","year":"2013","unstructured":"Lagatie O, Tritsmans L, Stuyver LJ (2013) The miRNA world of polyomaviruses. Virol J 10:268\u2013288","journal-title":"Virol J"},{"key":"560_CR24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","volume":"57","author":"P Lee","year":"2013","unstructured":"Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M (2013) A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57:141\u2013146","journal-title":"J Clin Virol"},{"key":"560_CR25","doi-asserted-by":"crossref","first-page":"e100036","DOI":"10.1371\/journal.pone.0100036","volume":"9","author":"A Link","year":"2014","unstructured":"Link A, Balaguer F, Nagasaka T, Boland CR, Goel A (2014) MicroRNA miR-J1-5p as a potential biomarker for JC virus infection in the gastrointestinal tract. PLoS One 9:e100036","journal-title":"PLoS One"},{"key":"560_CR26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.mcp.2010.04.002","volume":"24","author":"S Lu","year":"2010","unstructured":"Lu S, Smith AP, Moore D, Lee NM (2010) Different real-time PCR systems yield different gene expression values. Mol Cell Probes 24:315\u2013320","journal-title":"Mol Cell Probes"},{"key":"560_CR27","doi-asserted-by":"crossref","first-page":"e1927","DOI":"10.1002\/rmv.1927","volume":"27","author":"F Martelli","year":"2017","unstructured":"Martelli F, Giannecchini S (2017) Polyomavirus microRNAs circulating in biological fluids during viral persistence. Rev Med Virol 27:e1927","journal-title":"Rev Med Virol"},{"key":"560_CR28","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1177\/1352458514534513","volume":"20","author":"M Munoz-Culla","year":"2014","unstructured":"Munoz-Culla M, Irizar H, Castillo-Trivino T, Saenz-Cuesta M, Sepulveda L, Lopetegi I, Lopez de Munain A, Olascoaga J, Baranzini SE, Otaegui D (2014) Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler 20:1851\u20131859","journal-title":"Mult Scler"},{"key":"560_CR29","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","volume":"19","author":"T Olsson","year":"2013","unstructured":"Olsson T, Achiron A, Alfredsson L, Berger T, Brassat D, Chan A, Comi G, Eraksoy M, Hegen H, Hillert J, Jensen PE, Moiola L, Myhr KM, Oturai A, Schippling S, Siva A, Sorensen PS, Trampe AK, Weber T, Potts J, Plavina T, Paes D, Subramanyam M, Wiendl H, Dib H, Uren D, Hemmer B, Buck D (2013) Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler 19:1533\u20131538","journal-title":"Mult Scler"},{"key":"560_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2015.01.019","volume":"65","author":"T Pietila","year":"2015","unstructured":"Pietila T, Nummi M, Auvinen P, Mannonen L, Auvinen E (2015) Expression of BKV and JCV encoded microRNA in human cerebrospinal fluid, plasma and urine. J Clin Virol 65:1\u20135","journal-title":"J Clin Virol"},{"key":"560_CR31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML. Ann Neurol 76:802\u2013812","journal-title":"Ann Neurol"},{"key":"560_CR32","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, Investigators AFFIRM (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"key":"560_CR33","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald criteria\". Ann Neurol 58:840\u2013846","journal-title":"Ann Neurol"},{"key":"560_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2015.06.104","volume":"70","author":"A Rocca","year":"2015","unstructured":"Rocca A, Martelli F, Delbue S, Ferrante P, Bartolozzi D, Azzi A, Giannecchini S (2015) The JCPYV DNA load inversely correlates with the viral microrna expression in blood and cerebrospinal fluid of patients at risk of PML. J Clin Virol 70:1\u20136","journal-title":"J Clin Virol"},{"key":"560_CR35","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.22107","volume":"68","author":"RA Rudick","year":"2010","unstructured":"Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, Goelz SE (2010) Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 68:304\u2013310","journal-title":"Ann Neurol"},{"key":"560_CR36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","volume":"81","author":"N Schwab","year":"2013","unstructured":"Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Gobel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfar A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kumpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H (2013) L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 81:865\u2013871","journal-title":"Neurology"},{"key":"560_CR37","doi-asserted-by":"crossref","first-page":"9823","DOI":"10.1128\/JVI.01144-08","volume":"82","author":"GJ Seo","year":"2008","unstructured":"Seo GJ, Fink LH, O'Hara B, Atwood WJ, Sullivan CS (2008) Evolutionarily conserved function of a viral microRNA. J Virol 82:9823\u20139828","journal-title":"J Virol"},{"key":"560_CR38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.leu.2403590","volume":"19","author":"M Silvy","year":"2005","unstructured":"Silvy M, Mancini J, Thirion X, Sigaux F, Gabert J (2005) Evaluation of real-time quantitative PCR machines for the monitoring of fusion gene transcripts using the Europe against cancer protocol. Leukemia 19:305\u2013307","journal-title":"Leukemia"},{"key":"560_CR39","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.24371","volume":"77","author":"HS Wollebo","year":"2015","unstructured":"Wollebo HS, White MK, Gordon J, Berger JR, Khalili K (2015) Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 77:560\u2013570","journal-title":"Ann Neurol"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-017-0560-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-017-0560-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-017-0560-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T10:47:18Z","timestamp":1508842038000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-017-0560-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,22]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1007\/s13365-017-0560-x","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,22]]}}}